AB-001 clinical trials
Also written AB001.
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2015
How each study uses AB-001 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- AB001
- 3
Studies by the year they started
3 studies that test it; most in 2015 (1)
| Year | Studies |
|---|---|
| 2015 | 1 |
| 2019 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test AB-001.
- Nov 2027Study of Alpha Radioligand Therapy AB001 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)Phase 1 · ARTBIO Inc.
Studies
Open first, then newest update. How each study uses AB-001 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- Study of Alpha Radioligand Therapy AB001 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)Active, not recruitingPhase 1ARTBIO Inc.NCT07214961Written as AB001
- Tolerability, Safety and Pharmacokinetics of a Topical AB001 Patch in Healthy SubjectsCompletedPhase 1Frontier Biotechnologies Inc.NCT03997734Written as AB001
- A Study of a Topical Patch (AB001) in Patients With Chronic Low Back PainCompletedPhase 2Frontier Biotechnologies Inc.NCT02436824Written as AB001 patch